Tumor pyruvate kinase M2:A promising molecular target of gastrointestinal cancer

被引：2
|
作者：
Chen Guo [1 ]
Guan Li [2 ]
Jianing Hou [2 ]
Xingming Deng [2 ]
Sheng Ao [2 ]
Zhuofei Li [2 ]
Guoqing Lyu [2 ]
机构：
[1] Department of Biology,Southern University of Science and Technology
[2] Department of Gastrointestinal Surgery,Peking University Shenzhen Hospital
来源：
Chinese Journal of Cancer Research | 2018年 / 30卷 / 06期
关键词：
PKM2(pyruvate kinase M2); metabolic reprogramming; gene transcription; gastrointestinal cancer; therapy targets;
D O I：
暂无
中图分类号：
R735 [消化系肿瘤];
学科分类号：
摘要：
Gastrointestinal(GI) cancer is one of the most common causes of cancer-related deaths worldwide.Tumor markers are valuable in detecting post-surgical recurrence or in monitoring response to chemotherapy.Pyruvate kinase isoform M2(PKM2),a glycolytic enzyme catalyzing conversion of phosphoenolpyruvate(PEP) to pyruvate,confers a growth advantage to the tumor cells and enables them to adapt to the tumor microenvironment.In this review,we have summarized current research on the expression and regulation of PKM2 in tumor cells,and its potential role in GI carcinogenesis and progression.Furthermore,we have also discussed the potential of PKM2 as a diagnostic and screening marker,and a therapeutic target in GI cancer.
引用
收藏
页码：669 / 676
页数：8
相关论文
共 50 条
  • [31] CURRENT STATUS OF FECAL TUMOR M2 PYRUVATE KINASE IN COLORECTAL CANCER SCREENING
    Ewald, N.
    Tonus, C.
    Koss, K.
    McLoughlin, R. M.
    Hardt, P. D.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3276 - 3276
  • [32] Fecal pyruvate kinase M2 (tumor-M2PK) measurement: A new screening concept for colorectal cancer (CRC) with promising perspectives
    不详
    ANTICANCER RESEARCH, 2005, 25 (6D) : 4776 - 4776
  • [33] Pyruvate kinase M2 at a glance
    Yang, Weiwei
    Lu, Zhimin
    JOURNAL OF CELL SCIENCE, 2015, 128 (09) : 1655 - 1660
  • [34] Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics
    Zhu, Susi
    Guo, Yeye
    Zhang, Xu
    Liu, Hong
    Yin, Mingzhu
    Chen, Xiang
    Peng, Cong
    CANCER LETTERS, 2021, 503 : 240 - 248
  • [35] M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth
    Cortes-Cros, Marta
    Hemmerlin, Christelle
    Ferretti, Stephane
    Zhang, Juan
    Gounarides, John S.
    Yin, Hong
    Muller, Alban
    Haberkorn, Anne
    Chene, Patrick
    Sellers, William R.
    Hofmann, Francesco
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (02) : 489 - 494
  • [36] Tumor M2 pyruvate kinase in plasma of patients with urological tumors
    Roigas, J
    Schulze, G
    Raytarowski, S
    Jung, K
    Schnorr, D
    Leoning, SA
    TUMOR BIOLOGY, 2001, 22 (05) : 282 - 285
  • [37] Tumor M2 pyruvate kinase -: determination in breast cancer patients receiving trastuzumab therapy
    Hoopmann, M
    Warm, M
    Mallmann, P
    Thomas, A
    Göhring, UJ
    Schöndorf, T
    CANCER LETTERS, 2002, 187 (1-2) : 223 - 228
  • [38] Ferrocene-based modulators of cancer-associated tumor pyruvate kinase M2
    Jadhav, Jyotika
    Das, Rudradip
    Kamble, Sayali
    Chowdhury, Moumita Ghosh
    Kapoor, Saumya
    Gupta, Astha
    Vyas, Het
    Shard, Amit
    JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2022, 968
  • [39] Berberine Inhibited the Proliferation of Cancer Cells by Suppressing the Activity of Tumor Pyruvate Kinase M2
    Li, Zhichao
    Li, Hanging
    Lu, Yangxu
    Yang, Peng
    Li, Zhuoyu
    NATURAL PRODUCT COMMUNICATIONS, 2017, 12 (09) : 1415 - 1418
  • [40] 2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2
    Yoon, Yae Jin
    Kim, Young-Hwan
    Jin, Yena
    Chi, Seung-Wook
    Moon, Jeong Hee
    Han, Dong Cho
    Kwon, Byoung-Mog
    CANCER LETTERS, 2018, 434 : 42 - 55
12345